Kayte Spector-Bagdady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kayte Spector-Bagdady has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Kaitlyn Jaffe
Department of Health Promotion and Policy, University of Massachusetts Amherst, 715 North Pleasant Street, Amherst, MA 01003, United States; BC Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada
5 shared publicationsChris D. Krenz
Boston University, Boston, Massachusetts, USA
4 shared publicationsJ. Denard Thomas
Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School
4 shared publicationsJ. Scott Roberts
Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School
4 shared publicationsKerry A. Ryan
Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School
4 shared publicationsAmy L. McGuire
Baylor College of Medicine, Houston, Texas, USA
3 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Identifying "Identifiability:" From Regulatory Illusions to Techno-normative Frameworks to Protect Health Data Privacy
The foundational assumption underlying U.S. health data governance – that data are either "identified" and protected or "de-identified" and unregulated – is both legally incoherent and technically obsolete. Enacted when de-identification seemed a plausible safeguard, the HIPAA Privacy Rule codified this binary into law. HIPAA offers two de-identification pathways: expert determination and the safe harbor method. Institutional incentives have driven near-universal adoption of the safe harbor, producing , a form of legal endogeneity in which symbolic compliance with the eighteen HIPAA enumerated identifiers became mistaken for substantive privacy protection. The Common Rule's divergent identifiability definition has compounded this incoherence, and recent NIH attempts to contractually harmonize these conflicting standards represent regulatory surrender rather than reform.Re-identifiability is not a binary condition but a multi-dimensional, temporally shifting continuum shaped by the availability of external key data, evolving adversarial capabilities (including machine learning and AI), and the motivation of those seeking privacy breaches. Re-identification risk is also distributed inequitably, falling disproportionately on minoritized populations and individuals with rare conditions – precisely those whose data hold the greatest potential for advancing health equity. The binary regulatory framework not only fails to address this heterogeneity but actively reproduces its structural inequities.Drawing on Lessig's theory of regulatory modalities, we argue that privacy governance is an architectural problem as much as a legal one. Effective governance must redesign the architecture of data systems, not merely update their legal labels. We review novel technical approaches including k-anonymity frameworks, tiered access systems, controlled-access enclaves, and context-responsive suppression. We then begin to elucidate what level of re-identification risk is ethically acceptable for what data. Critically, the achievement of "privacy" cannot be resolved by technical thresholds alone.We ground these arguments in our experience designing the National Dementia Workforce Study (NDWS) secure data enclave, contrasting our approach with the All of Us Research Program. Both cases demonstrate that meaningful expert determination already occurs through iterative, multidisciplinary deliberation among lawyers, bioethicists, data scientists, and community representatives, and not through fixed methodologies.Federal regulators need not undertake the Sisyphean task of overhauling HIPAA to begin meaningful reform. What is required is a deliberate shift away from safe harbor compliance as a default, toward ML-enabled expert determination-grounded governance frameworks as adaptive and equitable as the risks they govern.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIdentifying "Identifiability:" From Regulatory Illusions to Techno-normative Frameworks to Protect Health Data Privacy
The foundational assumption underlying U.S. health data governance – that data are either "identified" and protected or "de-identified" and unregulated – is both legally incoherent and technically obsolete. Enacted when de-identification seemed a plausible safeguard, the HIPAA Privacy Rule codified this binary into law. HIPAA offers two de-identification pathways: expert determination and the safe harbor method. Institutional incentives have driven near-universal adoption of the safe harbor, producing , a form of legal endogeneity in which symbolic compliance with the eighteen HIPAA enumerated identifiers became mistaken for substantive privacy protection. The Common Rule's divergent identifiability definition has compounded this incoherence, and recent NIH attempts to contractually harmonize these conflicting standards represent regulatory surrender rather than reform.Re-identifiability is not a binary condition but a multi-dimensional, temporally shifting continuum shaped by the availability of external key data, evolving adversarial capabilities (including machine learning and AI), and the motivation of those seeking privacy breaches. Re-identification risk is also distributed inequitably, falling disproportionately on minoritized populations and individuals with rare conditions – precisely those whose data hold the greatest potential for advancing health equity. The binary regulatory framework not only fails to address this heterogeneity but actively reproduces its structural inequities.Drawing on Lessig's theory of regulatory modalities, we argue that privacy governance is an architectural problem as much as a legal one. Effective governance must redesign the architecture of data systems, not merely update their legal labels. We review novel technical approaches including k-anonymity frameworks, tiered access systems, controlled-access enclaves, and context-responsive suppression. We then begin to elucidate what level of re-identification risk is ethically acceptable for what data. Critically, the achievement of "privacy" cannot be resolved by technical thresholds alone.We ground these arguments in our experience designing the National Dementia Workforce Study (NDWS) secure data enclave, contrasting our approach with the All of Us Research Program. Both cases demonstrate that meaningful expert determination already occurs through iterative, multidisciplinary deliberation among lawyers, bioethicists, data scientists, and community representatives, and not through fixed methodologies.Federal regulators need not undertake the Sisyphean task of overhauling HIPAA to begin meaningful reform. What is required is a deliberate shift away from safe harbor compliance as a default, toward ML-enabled expert determination-grounded governance frameworks as adaptive and equitable as the risks they govern.
- Open Access
- 13 April 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 152, 105278
Uncovered, underfunded, and undervalued: How policy contexts shape knowledge production in multi-site substance use trials
- 13 April 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 152, 105278
Open AccessUncovered, underfunded, and undervalued: How policy contexts shape knowledge production in multi-site substance use trials
- Open Access
- 2 January 2026
- Published by Taylor & Francis in AJOB Empirical Bioethics
- Vol. 17 (1) , 20-29
Differences Between Government, Consortium, and Private Database Stewards Impacting the Genomic Data Market: A Survey of U.S. Academic Genetic Researchers
Despite major shifts in U.S. federal government data sharing requirements, their impact, and relation to researcher choice of database, are underexplored. This study surveyed genetic researchers regarding trends, priorities, perceptions of quality, impact on research outcomes, and genomic data sharing and use across government, consortium, and private databases. As part of an exploratory sequential mixed methods project, we surveyed 294 U.S.-based genomic academic researchers. Genetic researchers generally have a choice between databases, which allows them to prioritize data quality. This might explain recent trends toward the use of government and consortium databases away from private ones. Respondents reported several significant differences in the requirements that different data stewards place on them, which impact their work. Private data stewards generally had the most restrictions and were the least likely to allow users to release the full dataset at completion, despite over 50% of respondents reporting the use of federal funds for such research. Our findings indicate that upstream benefits (i.e., access, database features) are more impactful on researchers' choice in databases than downstream publication limitations (e.g., co-authorship, limited data release). Respondents also reported the time necessary to share data as the biggest barrier to contributing to government databases and non-comprehensiveness as the biggest challenge to using existing government data. The federal government can leverage these findings about researcher priorities to continue attracting researchers, to push forward goals related to open science and enabling advances for patients underrepresented in genetic research, and to found new genomic data sharing policy moving forward.
- 2 January 2026
- Published by Taylor & Francis in AJOB Empirical Bioethics
- Vol. 17 (1) , 20-29
Open AccessDifferences Between Government, Consortium, and Private Database Stewards Impacting the Genomic Data Market: A Survey of U.S. Academic Genetic Researchers
Despite major shifts in U.S. federal government data sharing requirements, their impact, and relation to researcher choice of database, are underexplored. This study surveyed genetic researchers regarding trends, priorities, perceptions of quality, impact on research outcomes, and genomic data sharing and use across government, consortium, and private databases. As part of an exploratory sequential mixed methods project, we surveyed 294 U.S.-based genomic academic researchers. Genetic researchers generally have a choice between databases, which allows them to prioritize data quality. This might explain recent trends toward the use of government and consortium databases away from private ones. Respondents reported several significant differences in the requirements that different data stewards place on them, which impact their work. Private data stewards generally had the most restrictions and were the least likely to allow users to release the full dataset at completion, despite over 50% of respondents reporting the use of federal funds for such research. Our findings indicate that upstream benefits (i.e., access, database features) are more impactful on researchers' choice in databases than downstream publication limitations (e.g., co-authorship, limited data release). Respondents also reported the time necessary to share data as the biggest barrier to contributing to government databases and non-comprehensiveness as the biggest challenge to using existing government data. The federal government can leverage these findings about researcher priorities to continue attracting researchers, to push forward goals related to open science and enabling advances for patients underrepresented in genetic research, and to found new genomic data sharing policy moving forward.
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 13 (1)
Putting the L in ELSI: legal methods for bioethics research
Lawyers and law professors are increasingly involved in interdisciplinary scientific teams and grant research to answer ethical, legal and policy questions related to biomedical topics. Yet, the methods that lawyers use to conduct legal research and analysis are not always familiar to scientists and social scientists conducting peer review of a proposed project with legal aims or a publication reporting a legal study. To better facilitate interdisciplinary ethical, legal, and social implications collaboration, there is a need to better explain how legal research methodologies can provide robust tools to address a range of nuanced biomedical questions. This paper explores legal research and analysis methodologies relevant to federally funded research and scientific inquiry. It sets out different ways that legal research and analysis can advance and support biomedical, bioethics, and health law research and then demonstrates how these benefits can be realized using case studies from existing literature.
- 1 January 2026
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 13 (1)
Open AccessPutting the L in ELSI: legal methods for bioethics research
Lawyers and law professors are increasingly involved in interdisciplinary scientific teams and grant research to answer ethical, legal and policy questions related to biomedical topics. Yet, the methods that lawyers use to conduct legal research and analysis are not always familiar to scientists and social scientists conducting peer review of a proposed project with legal aims or a publication reporting a legal study. To better facilitate interdisciplinary ethical, legal, and social implications collaboration, there is a need to better explain how legal research methodologies can provide robust tools to address a range of nuanced biomedical questions. This paper explores legal research and analysis methodologies relevant to federally funded research and scientific inquiry. It sets out different ways that legal research and analysis can advance and support biomedical, bioethics, and health law research and then demonstrates how these benefits can be realized using case studies from existing literature.
- Open Access
- 23 September 2025
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 25 (12) , 4-18
The Genetic Data Market: Institutional Governance of Academic/Industry Research Partnerships for the Public Good
The Trump Administration's cuts to research funding and opposition to diversity, equity, and inclusion is destabilizing academic research. These attacks coincide with pointed government support for the private sector. But the conceptualization of academic versus private sector health research has historically been a false binary. Drawing on mixed methods research, this paper examines the genomic data market as an example of advantages and challenges of commercializing academic expertise. It also highlights the structural downsides of researchers individually navigating industry partnerships. While academia is currently being put in the unenviable position of being more likely to need the private sector to conduct research, with less federal funding to offer in exchange, structural pain points have existed for decades. This is an opportunity for academia to harness its powers of expertise and collective action to develop institutional policy to ensure academic/industry research is beneficial to the public health and diverse patient communities.
- 23 September 2025
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 25 (12) , 4-18
Open AccessThe Genetic Data Market: Institutional Governance of Academic/Industry Research Partnerships for the Public Good
The Trump Administration's cuts to research funding and opposition to diversity, equity, and inclusion is destabilizing academic research. These attacks coincide with pointed government support for the private sector. But the conceptualization of academic versus private sector health research has historically been a false binary. Drawing on mixed methods research, this paper examines the genomic data market as an example of advantages and challenges of commercializing academic expertise. It also highlights the structural downsides of researchers individually navigating industry partnerships. While academia is currently being put in the unenviable position of being more likely to need the private sector to conduct research, with less federal funding to offer in exchange, structural pain points have existed for decades. This is an opportunity for academia to harness its powers of expertise and collective action to develop institutional policy to ensure academic/industry research is beneficial to the public health and diverse patient communities.
- Open Access
- 27 March 2025
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 53 (1) , 74-79
The Need for Prospective Integrity Standards for the Use of Generative AI in Research
The federal government has a long history of trying to find the right balance in supporting scientific and medical research while protecting the public and other researchers from potential harms. To date, this balance has been generally calibrated differently across contexts – including in clinical care, human subjects research, and research integrity. New challenges continue to face this disparate model of regulation, including novel Generative Artificial Intelligence (GenAI) tools. Because of potential increases in unintentional fabrication, falsification, and plagiarism using GenAI – and challenges establishing both these errors and intentionality in retrospect – this article argues that we should instead move toward a system that sets accepted community standards for the use of GenAI in research as prospective requirements.
- 27 March 2025
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 53 (1) , 74-79
Open AccessThe Need for Prospective Integrity Standards for the Use of Generative AI in Research
The federal government has a long history of trying to find the right balance in supporting scientific and medical research while protecting the public and other researchers from potential harms. To date, this balance has been generally calibrated differently across contexts – including in clinical care, human subjects research, and research integrity. New challenges continue to face this disparate model of regulation, including novel Generative Artificial Intelligence (GenAI) tools. Because of potential increases in unintentional fabrication, falsification, and plagiarism using GenAI – and challenges establishing both these errors and intentionality in retrospect – this article argues that we should instead move toward a system that sets accepted community standards for the use of GenAI in research as prospective requirements.
- 25 February 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (8) , 665-666
Protecting Privacy When Genetic Databases Are Commercialized
This Viewpoint questions whether people’s health data obtained in direct-to-consumer genetic testing can be used, shared, or marketed in the future.
- 25 February 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (8) , 665-666
Protecting Privacy When Genetic Databases Are Commercialized
This Viewpoint questions whether people’s health data obtained in direct-to-consumer genetic testing can be used, shared, or marketed in the future.
- 24 February 2025
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 25 (3) , 1-3
Disclosure as Absolution in Medicine: Disentangling Autonomy from Beneficence and Justice in Artificial Intelligence
- 24 February 2025
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 25 (3) , 1-3
Disclosure as Absolution in Medicine: Disentangling Autonomy from Beneficence and Justice in Artificial Intelligence
- Open Access
- 22 October 2024
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 52 (2) , 399-411
“A Double-Edged Sword”: A Brief History of Genomic Data Governance and Genetic Researcher Perspectives on Data Sharing
As the federal government continues to expand upon and improve its data sharing policies over the past 20 years, complex challenges remain. Our interviews with U.S. academic genetic researchers (n=23) found that the burden, translation, industry limitations, and consent structure of data sharing remain major governance challenges.
- 22 October 2024
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 52 (2) , 399-411
Open Access“A Double-Edged Sword”: A Brief History of Genomic Data Governance and Genetic Researcher Perspectives on Data Sharing
As the federal government continues to expand upon and improve its data sharing policies over the past 20 years, complex challenges remain. Our interviews with U.S. academic genetic researchers (n=23) found that the burden, translation, industry limitations, and consent structure of data sharing remain major governance challenges.
- Open Access
- 13 September 2024
- Published by Wiley in Learning Health Systems
- Vol. 9 (1) , e10450
Lessons for a learning health system: Effectively communicating to patients about research with their health information and biospecimens
Introduction: Sharing patient health information and biospecimens can improve health outcomes and accelerate breakthroughs in medical research. But patients generally lack understanding of how their clinical data and biospecimens are used or commercialized for research. In this mixed methods project, we assessed the impact of communication materials on patient understanding, attitudes, and perceptions.Methods: Michigan Medicine patients were recruited for a survey (n = 480) or focus group (n = 33) via a web‐based research study portal. The survey assessed the impact of mode of communication about health data and biospecimen sharing (via an informational poster vs. a news article) on patient perceptions of privacy, transparency, comfort, respect, and trust. Focus groups provided in‐depth qualitative feedback on three communication materials, including a poster, FAQ webpage, and a consent form excerpt.Results: Among survey respondents, the type of intervention (poster vs. news) made no statistically significant difference in its influence on any characteristic. However, 95% preferred that Michigan Medicine tell them about patient data and biospecimen research sharing versus hearing it from the news. Focus group participants provided additional insights, discussing values and perceptions of altruism and reciprocity, concerns about commercialization, privacy, and security; and the desire for consent, control, and transparency.Conclusion: Developing our understanding of patient data‐sharing practices and integrating patient preferences into health system policy, through this work and continued exploration, contributes to building infrastructure that can be used to support the development of a learning health system across hospital systems nationally.
- 13 September 2024
- Published by Wiley in Learning Health Systems
- Vol. 9 (1) , e10450
Open AccessLessons for a learning health system: Effectively communicating to patients about research with their health information and biospecimens
Introduction: Sharing patient health information and biospecimens can improve health outcomes and accelerate breakthroughs in medical research. But patients generally lack understanding of how their clinical data and biospecimens are used or commercialized for research. In this mixed methods project, we assessed the impact of communication materials on patient understanding, attitudes, and perceptions.Methods: Michigan Medicine patients were recruited for a survey (n = 480) or focus group (n = 33) via a web‐based research study portal. The survey assessed the impact of mode of communication about health data and biospecimen sharing (via an informational poster vs. a news article) on patient perceptions of privacy, transparency, comfort, respect, and trust. Focus groups provided in‐depth qualitative feedback on three communication materials, including a poster, FAQ webpage, and a consent form excerpt.Results: Among survey respondents, the type of intervention (poster vs. news) made no statistically significant difference in its influence on any characteristic. However, 95% preferred that Michigan Medicine tell them about patient data and biospecimen research sharing versus hearing it from the news. Focus group participants provided additional insights, discussing values and perceptions of altruism and reciprocity, concerns about commercialization, privacy, and security; and the desire for consent, control, and transparency.Conclusion: Developing our understanding of patient data‐sharing practices and integrating patient preferences into health system policy, through this work and continued exploration, contributes to building infrastructure that can be used to support the development of a learning health system across hospital systems nationally.